1. Home
  2. BRSP vs CAPR Comparison

BRSP vs CAPR Comparison

Compare BRSP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrightSpire Capital Inc.

BRSP

BrightSpire Capital Inc.

SELL

Current Price

$3.70

Market Cap

528.9M

Sector

Real Estate

ML Signal

SELL

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$6.77

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRSP
CAPR
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
528.9M
584.9M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
BRSP
CAPR
Price
$3.70
$6.77
Analyst Decision
Buy
Buy
Analyst Count
8
10
Target Price
$5.97
★ $27.00
AVG Volume (30 Days)
1.9M
★ 2.5M
Earning Date
10-27-2026
11-09-2026
Dividend Yield
★ 16.89%
N/A
EPS Growth
★ 75.24
N/A
EPS
★ N/A
N/A
Revenue
★ $330,587,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.19
$1.52
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.70
$2.96
52 Week High
$6.17
$40.37

Technical Indicators

Market Signals
Indicator
BRSP
CAPR
Relative Strength Index (RSI) 29.26 39.26
Support Level N/A $6.01
Resistance Level $3.94 $10.12
Average True Range (ATR) 0.11 0.53
MACD 0.02 -0.15
Stochastic Oscillator 10.34 9.03

Price Performance

Historical Comparison
BRSP
CAPR

About BRSP BrightSpire Capital Inc.

BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: